Quick Answer
Indivior Pharmaceuticals, Inc. reported Stockholders Equity of -$98.00 million for the year ending 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +70.9% in Stockholders Equity from 2024 to 2025.
- This data is from Indivior Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$161.00 million | Q2 2024: -$281.00 million | Q3 2024: -$310.00 million | Q1 2025: -$285.00 million | Q2 2025: -$257.00 million | Q3 2025: -$207.00 million.
- Over the full 5 years of available data (2021 to 2025), Indivior Pharmaceuticals, Inc.'s Stockholders Equity has declined by 181.0%.
- Historical annual values: Fiscal year 2025: -$98.00 million | Fiscal year 2024: -$337.00 million | Fiscal year 2023: -$184.00 million | Fiscal year 2022: -$15.00 million | Fiscal year 2021: $121.00 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: